MersV1, PascalFrancis, Curation, bibRecord, 000118

Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus

Identifieur interne : 000118 ( PascalFrancis/Curation ); précédent : 000117

Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus

Auteurs : Y. E. Khudyakov [États-Unis, Inde] ; E. N. Lopareva [États-Unis, Inde] ; D. L. Jue [Inde, États-Unis] ; T. K. Crews [Inde, États-Unis] ; S. P. Thyagarajan [Inde] ; H. A. Fields [États-Unis, Inde]

Source :

Journal of clinical microbiology [ 0095-1137 ] ; 1999.

RBID : Pascal:99-0464209

Descripteurs français

Pascal (Inist)
- Virus hépatite E, Déterminant antigénique, Peptide, Identification, Relation structure propriété, Domaine moléculaire, Antigénicité, Protéine ORF2.

English descriptors

KwdEn :
- Antigenic determinant, Antigenicity, Hepatitis E virus, Identification, Molecular domain, Peptides, Property structure relationship.

Abstract

The antigenic composition of the hepatitis E virus (HEV) protein encoded by open reading frame 2 (ORF2) was determined by using synthetic peptides. Three sets of overlapping 18-, 25-, and 30-mer peptides, with each set spanning the entire ORF2 protein of the HEV Burma strain, were synthesized. All synthetic peptides were tested by enzyme immunoassay against a panel of 32 anti-HEV-positive serum specimens obtained from acutely HEV-infected persons. Six antigenic domains within the ORF2 protein were identified. Domains 1 and 6 located at the N and C termini of the ORF2 protein, respectively, contain strong immunoglobulin G (IgG) and IgM antigenic epitopes that can be efficiently modeled with peptides of different sizes. In contrast, antigenic epitopes identified within the two central domains (3 and 4) were modeled more efficiently with 30-mer peptides than with either 18- or 25-mers. Domain 2 located at amino acids (aa) 143 to 222 was modeled best with 25-mer peptides. A few 30-mer synthetic peptides derived from domain 5 identified at aa 490 to 579 demonstrated strong IgM antigenic reactivity. Several 30-mer synthetic peptides derived from domains 1, 4, and 6 immunoreacted with IgG or IgM with more than 70% of anti-HEV-positive serum specimens. Thus, the results of this study demonstrate the existence of six diagnostically relevant antigenic domains within the HEV ORF2 protein.

A01	`01`	`1`		`@0 0095-1137`
A02	`01`			`@0 JCMIDW`
A03		`1`		`@0 J. clin. microbiol.`
A05				`@2 37`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus`
A11	`01`	`1`		`@1 KHUDYAKOV (Y. E.)`
A11	`02`	`1`		`@1 LOPAREVA (E. N.)`
A11	`03`	`1`		`@1 JUE (D. L.)`
A11	`04`	`1`		`@1 CREWS (T. K.)`
A11	`05`	`1`		`@1 THYAGARAJAN (S. P.)`
A11	`06`	`1`		`@1 FIELDS (H. A.)`
A14	`01`			`@1 Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services @2 Atlanta, Georgia @3 USA @Z 1 aut. @Z 2 aut. @Z 6 aut.`
A14	`02`			`@1 Department of Microbiology, University of Madras @2 Madras @3 IND @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A14	`03`			`@1 Biotechnology Core Facility Branch, Scientific Resources, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services @2 Atlanta, Georgia @3 USA @Z 3 aut. @Z 4 aut.`
A20				`@1 2863-2871`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17088 @5 354000089458010220`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 43 ref.`
A47	`01`	`1`		`@0 99-0464209`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of clinical microbiology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The antigenic composition of the hepatitis E virus (HEV) protein encoded by open reading frame 2 (ORF2) was determined by using synthetic peptides. Three sets of overlapping 18-, 25-, and 30-mer peptides, with each set spanning the entire ORF2 protein of the HEV Burma strain, were synthesized. All synthetic peptides were tested by enzyme immunoassay against a panel of 32 anti-HEV-positive serum specimens obtained from acutely HEV-infected persons. Six antigenic domains within the ORF2 protein were identified. Domains 1 and 6 located at the N and C termini of the ORF2 protein, respectively, contain strong immunoglobulin G (IgG) and IgM antigenic epitopes that can be efficiently modeled with peptides of different sizes. In contrast, antigenic epitopes identified within the two central domains (3 and 4) were modeled more efficiently with 30-mer peptides than with either 18- or 25-mers. Domain 2 located at amino acids (aa) 143 to 222 was modeled best with 25-mer peptides. A few 30-mer synthetic peptides derived from domain 5 identified at aa 490 to 579 demonstrated strong IgM antigenic reactivity. Several 30-mer synthetic peptides derived from domains 1, 4, and 6 immunoreacted with IgG or IgM with more than 70% of anti-HEV-positive serum specimens. Thus, the results of this study demonstrate the existence of six diagnostically relevant antigenic domains within the HEV ORF2 protein.
C02	`01`	`X`		`@0 002A05C03`
C03	`01`	`X`	`FRE`	`@0 Virus hépatite E @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Hepatitis E virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Hepatitis E virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Déterminant antigénique @5 02`
C03	`02`	`X`	`ENG`	`@0 Antigenic determinant @5 02`
C03	`02`	`X`	`SPA`	`@0 Determinante antigénico @5 02`
C03	`03`	`X`	`FRE`	`@0 Peptide @5 03`
C03	`03`	`X`	`ENG`	`@0 Peptides @5 03`
C03	`03`	`X`	`SPA`	`@0 Péptido @5 03`
C03	`04`	`X`	`FRE`	`@0 Identification @5 04`
C03	`04`	`X`	`ENG`	`@0 Identification @5 04`
C03	`04`	`X`	`SPA`	`@0 Identificación @5 04`
C03	`05`	`X`	`FRE`	`@0 Relation structure propriété @5 05`
C03	`05`	`X`	`ENG`	`@0 Property structure relationship @5 05`
C03	`05`	`X`	`SPA`	`@0 Relación estructura propiedad @5 05`
C03	`06`	`X`	`FRE`	`@0 Domaine moléculaire @5 06`
C03	`06`	`X`	`ENG`	`@0 Molecular domain @5 06`
C03	`06`	`X`	`SPA`	`@0 Dominio molecular @5 06`
C03	`07`	`X`	`FRE`	`@0 Antigénicité @5 07`
C03	`07`	`X`	`ENG`	`@0 Antigenicity @5 07`
C03	`07`	`X`	`SPA`	`@0 Antigenicidad @5 07`
C03	`08`	`X`	`FRE`	`@0 Protéine ORF2 @4 INC @5 79`
C07	`01`	`X`	`FRE`	`@0 Calicivirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Calicivirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Calicivirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Caliciviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Caliciviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Caliciviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 298`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000095

Links to Exploration step

Pascal:99-0464209

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus</title>
<author><name sortKey="Khudyakov, Y E" sort="Khudyakov, Y E" uniqKey="Khudyakov Y" first="Y. E." last="Khudyakov">Y. E. Khudyakov</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
<author><name sortKey="Lopareva, E N" sort="Lopareva, E N" uniqKey="Lopareva E" first="E. N." last="Lopareva">E. N. Lopareva</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
<author><name sortKey="Jue, D L" sort="Jue, D L" uniqKey="Jue D" first="D. L." last="Jue">D. L. Jue</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biotechnology Core Facility Branch, Scientific Resources, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2> Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Crews, T K" sort="Crews, T K" uniqKey="Crews T" first="T. K." last="Crews">T. K. Crews</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biotechnology Core Facility Branch, Scientific Resources, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2> Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Thyagarajan, S P" sort="Thyagarajan, S P" uniqKey="Thyagarajan S" first="S. P." last="Thyagarajan">S. P. Thyagarajan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
<author><name sortKey="Fields, H A" sort="Fields, H A" uniqKey="Fields H" first="H. A." last="Fields">H. A. Fields</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0464209</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0464209 INIST</idno>
<idno type="RBID">Pascal:99-0464209</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000095</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000118</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus</title>
<author><name sortKey="Khudyakov, Y E" sort="Khudyakov, Y E" uniqKey="Khudyakov Y" first="Y. E." last="Khudyakov">Y. E. Khudyakov</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
<author><name sortKey="Lopareva, E N" sort="Lopareva, E N" uniqKey="Lopareva E" first="E. N." last="Lopareva">E. N. Lopareva</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
<author><name sortKey="Jue, D L" sort="Jue, D L" uniqKey="Jue D" first="D. L." last="Jue">D. L. Jue</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biotechnology Core Facility Branch, Scientific Resources, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2> Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Crews, T K" sort="Crews, T K" uniqKey="Crews T" first="T. K." last="Crews">T. K. Crews</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biotechnology Core Facility Branch, Scientific Resources, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2> Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Thyagarajan, S P" sort="Thyagarajan, S P" uniqKey="Thyagarajan S" first="S. P." last="Thyagarajan">S. P. Thyagarajan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
<author><name sortKey="Fields, H A" sort="Fields, H A" uniqKey="Fields H" first="H. A." last="Fields">H. A. Fields</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Inde</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical microbiology</title>
<title level="j" type="abbreviated">J. clin. microbiol.</title>
<idno type="ISSN">0095-1137</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical microbiology</title>
<title level="j" type="abbreviated">J. clin. microbiol.</title>
<idno type="ISSN">0095-1137</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigenic determinant</term>
<term>Antigenicity</term>
<term>Hepatitis E virus</term>
<term>Identification</term>
<term>Molecular domain</term>
<term>Peptides</term>
<term>Property structure relationship</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus hépatite E</term>
<term>Déterminant antigénique</term>
<term>Peptide</term>
<term>Identification</term>
<term>Relation structure propriété</term>
<term>Domaine moléculaire</term>
<term>Antigénicité</term>
<term>Protéine ORF2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The antigenic composition of the hepatitis E virus (HEV) protein encoded by open reading frame 2 (ORF2) was determined by using synthetic peptides. Three sets of overlapping 18-, 25-, and 30-mer peptides, with each set spanning the entire ORF2 protein of the HEV Burma strain, were synthesized. All synthetic peptides were tested by enzyme immunoassay against a panel of 32 anti-HEV-positive serum specimens obtained from acutely HEV-infected persons. Six antigenic domains within the ORF2 protein were identified. Domains 1 and 6 located at the N and C termini of the ORF2 protein, respectively, contain strong immunoglobulin G (IgG) and IgM antigenic epitopes that can be efficiently modeled with peptides of different sizes. In contrast, antigenic epitopes identified within the two central domains (3 and 4) were modeled more efficiently with 30-mer peptides than with either 18- or 25-mers. Domain 2 located at amino acids (aa) 143 to 222 was modeled best with 25-mer peptides. A few 30-mer synthetic peptides derived from domain 5 identified at aa 490 to 579 demonstrated strong IgM antigenic reactivity. Several 30-mer synthetic peptides derived from domains 1, 4, and 6 immunoreacted with IgG or IgM with more than 70% of anti-HEV-positive serum specimens. Thus, the results of this study demonstrate the existence of six diagnostically relevant antigenic domains within the HEV ORF2 protein.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0095-1137</s0>
</fA01>
<fA02 i1="01"><s0>JCMIDW</s0>
</fA02>
<fA03 i2="1"><s0>J. clin. microbiol.</s0>
</fA03>
<fA05><s2>37</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KHUDYAKOV (Y. E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LOPAREVA (E. N.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JUE (D. L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CREWS (T. K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>THYAGARAJAN (S. P.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FIELDS (H. A.)</s1>
</fA11>
<fA14 i1="01"><s1>Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Microbiology, University of Madras</s1>
<s2>Madras</s2>
<s3>IND</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Biotechnology Core Facility Branch, Scientific Resources, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services</s1>
<s2> Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>2863-2871</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17088</s2>
<s5>354000089458010220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>43 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0464209</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical microbiology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The antigenic composition of the hepatitis E virus (HEV) protein encoded by open reading frame 2 (ORF2) was determined by using synthetic peptides. Three sets of overlapping 18-, 25-, and 30-mer peptides, with each set spanning the entire ORF2 protein of the HEV Burma strain, were synthesized. All synthetic peptides were tested by enzyme immunoassay against a panel of 32 anti-HEV-positive serum specimens obtained from acutely HEV-infected persons. Six antigenic domains within the ORF2 protein were identified. Domains 1 and 6 located at the N and C termini of the ORF2 protein, respectively, contain strong immunoglobulin G (IgG) and IgM antigenic epitopes that can be efficiently modeled with peptides of different sizes. In contrast, antigenic epitopes identified within the two central domains (3 and 4) were modeled more efficiently with 30-mer peptides than with either 18- or 25-mers. Domain 2 located at amino acids (aa) 143 to 222 was modeled best with 25-mer peptides. A few 30-mer synthetic peptides derived from domain 5 identified at aa 490 to 579 demonstrated strong IgM antigenic reactivity. Several 30-mer synthetic peptides derived from domains 1, 4, and 6 immunoreacted with IgG or IgM with more than 70% of anti-HEV-positive serum specimens. Thus, the results of this study demonstrate the existence of six diagnostically relevant antigenic domains within the HEV ORF2 protein.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus hépatite E</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Hepatitis E virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hepatitis E virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Déterminant antigénique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Antigenic determinant</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Determinante antigénico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Peptide</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Peptides</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Péptido</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Identification</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Identification</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Identificación</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Relation structure propriété</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Property structure relationship</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Relación estructura propiedad</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Domaine moléculaire</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Molecular domain</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Dominio molecular</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antigénicité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antigenicity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antigenicidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Protéine ORF2</s0>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Calicivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Calicivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Calicivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Caliciviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Caliciviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Caliciviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>298</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000118 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000118 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:99-0464209
   |texte=   Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus

Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri